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Effect of the Ginger Derivative, 6-Shogaol, on Ferritin Levels in Patients
With Low to Intermediate-1-Risk Myelodysplastic Syndrome-A Small,
Investigative Study
Abstract
Background: Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal stem cell disorders
characterized by dysplastic and ineffective hematopoiesis and peripheral cytopenias. Elevated serum ferritin
(SF) is often observed in nontransfused, lower risk MDS. It has been reported that ineffective erythropoiesis
enhances iron absorption in MDS through downregulation of hepcidin and its prohormones such that SF
rises. Aim: To determine the effect of 6-shogaol, a dehydration derivative of ginger, known to have
hepatoprotective and chemotherapeutic activity, on 6 early-stage, transfusion-independent patients with
MDS, 3 of whom had raised levels of SF. Method: Six patients with MDS with low or intermediate-1 subtypes,
as defined by the International Prognostic Scoring System (IPSS), were recruited into the study and were
administered 1 gel capsule daily containing 20 mg ginger extract standardized for 20% 6-shogaol. Blood and
urine samples were collected and various markers monitored at regular intervals. Results: 6-shogaol caused a
decrease in SF levels in 3 of 6 patients with early MDS (50%) whose SF levels were elevated at the start of the
study. Our findings suggest upregulation of hepcidin and its prohormones, possibly through an improvement
in liver function. Discussion: In light of the encouraging results in this small, investigative study, we are
planning a larger study to confirm the beneficial effect of 6-shogaol in patients with raised ferritin levels due to
ineffective erythropoiesis.
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Myelodysplastic syndrome (MDS) is a heterogeneous group of 
clonal stem cell disorders characterized by dysplastic and inef-
fective hematopoiesis and peripheral cytopenias. The natural 
history of MDS is variable, ranging from the indolent condi-
tion spanning years, to a form rapidly progressing to acute 
myelogenous leukemia.1 The disease predominates in an 
elderly population, the median age being approximately 
70 years. Many of these patients also have numerous comorbid 
conditions which make the use of natural compounds, with lit-
tle or no toxicity, highly desirable in the lower risk MDS, 
defined by the International Prognostic Scoring System (IPSS) 
as low or intermediate-1 (Int-1) subtypes.
Elevated serum ferritin (SF) is often observed in non-
transfused, patients with lower risk MDS. Kikuchi et al2 eval-
uated baseline SF levels in nontransfused patients with MDS 
and found that the SF level was significantly higher in 
patients with MDS compared with healthy controls. They 
also found that the SF level of patients with higher risk MDS 
was significantly higher than that of the patients with lower 
risk MDS. These authors suggest that baseline SF level may 
be an independent prognostic factor for overall survival and 
leukemia-free survival (LFS) in patients with MDS as the 
LFS was significantly shorter in the high SF group than in 
the low SF group. High SF at diagnosis (>500 ng/mL) was 
significantly associated with future development of transfu-
sion dependency.
The liver polypeptide hepcidin plays a pivotal role in iron 
homeostasis. In macrophages, it accelerates the degradation of 
the transmembrane iron exporter ferroportin messenger RNA. 
In intestinal epithelial cells, it is believed to downregulate diva-
lent metal transporter 1, which is involved in the transfer of 
iron across the intestinal wall.3 It has been reported that inef-
fective erythropoiesis enhances iron absorption in MDS 
through downregulation of hepcidin and its prohormones such 
that SF rises.4
Plants of the ginger family have been credited with 
hepatoprotective activity.5,6 The substance called [6]-gin-
gerol is the main active compound in ginger root and the 
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one that gives ginger its distinctive flavor. Shogaols are the 
dehydration products of gingerols during storage or ther-
mal processing. Hepatoprotective effects of 6-shogaol have 
been found in animal studies against ethanol, carbon tetra-
chloride, diclofenac, and acetaminophen-induced hepato-
toxicity. Zhuang et  al6 identified that shogaol in 
ginger-derived nanoparticles specifically targets hepato-
cytes and plays a role in the induction of nuclear factor 
erythroid 2–related factor 2 (Nrf2). Nrf2 transcriptionally 
controls the gene expression of many cytoprotective 
enzymes and plays an important role in protecting liver 
against insults. A study by Alquasoumi et al5 showed that 
pretreatment of rats with 6-shogaol for 6 days exhibited a 
significant protective effect on diclofenac sodium-induced 
hepatic injury by reduction in serum aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), and alkaline 
phosphatase compared with controls. Their results showed 
that 6-shogaol prevented diclofenac sodium (DFS)-induced 
acute hepatotoxicity by protecting serum marker enzymes, 
bilirubin, and antioxidant activity.
Based on the above findings, we have conducted a small, 
investigative study to evaluate the effect of 6-shogaol in 6 early 
stages, transfusion-independent patients with MDS, 3 of 
whom had raised levels of SF.
Methods
Six patients with low or Int-1–risk MDS, as defined by the 
IPSS, were recruited into the study. The study was performed 
in the Department of Endocrinology at St George Hospital, 
Sydney, and informed consent was obtained from each patient 
before recruitment. Patients were administered 1 gel capsule 
daily containing 20 mg ginger extract standardized for 20% 
6-shogaol. Blood samples were drawn at baseline and at 
2-monthly intervals for a period of 6 months (initial study—i). 
Based on the decrease in SF levels shown in 3 of 6 patients 
with elevated SF and the improvement in liver function mark-
ers shown in 1 patient, the study was repeated on 2 of 3 patients 
for a further 6 months (repeat study—r) with a washout period 
of 3 months between the initial study and the repeat study. 
Markers monitored for the initial study (i) included full blood 
count, serum chemistry, liver function, reticulocyte count, 
Coombs test, and serum iron studies. Markers monitored for 
the repeat study (r) included full blood count, serum chemistry, 
liver function, and the add-on tests for 24-hour urine iron 
excretion and serum hepcidin levels.
Hepcidin was measured in serum using a highly precise 
and validated liquid chromatography method, incorporat-
ing online extraction and coupled with tandem mass 
spectrometry.7
Results
There were 4 men and 2 women with an average age of 
70 years in the study (Table 1). The mean disease duration 
was 5.6 years. Of the 6 patients, 5 patients (83%) completed 
the 6-month initial study. One patient (no. 5) stopped the 
initial study at month 4 and was lost to follow-up. Two 
patients, due to their decrease in SF levels (nos 1 and 3) in the 
initial study, were entered into the repeat study with a wash-
out period of 3 months, and both these patients completed 
the 6-month repeat study, ie, a total of 12 months shogaol 
therapy. None of the patients were treated with anything 
other than the 6-shogaol during the study period and none 
displayed ill effects from the 6-shogaol.
In the study, 4 of 6 (67%) patients were anemic at baseline 
and all had variable cytopenias (Table 1). There was no change 
in cell counts over the course of the initial or repeat study 
period.
Of the 6 patients, 3 (50%—nos 1, 3, 5) had elevated SF 
levels at baseline (Table 1). No sign of infection or inflamma-
tion was found in any of these patients. Patient no. 1 had a 
high alcohol intake which may have also contributed to his 
significantly high SF. All 3 patients showed a >40% decrease 
in SF by the end of the initial study period (Table 1). Patients 
1 and 3 repeated the study, with a 3-month washout period 
between the initial study and the repeat study. In patient 1, the 
decreased SF remained stable during the 3 month washout 
period. Once shogaol therapy was recommenced, SF contin-
ued to decrease from baseline by the end of the repeat study 
(51% decrease from baseline in initial study and 58% decrease 
from baseline by the end of the repeat study; Figure 1). Urinary 
iron excretion was measured in the 2 patients participating in 
the repeat study and there was no effect of the 6-shogaol on 
urinary iron excretion.
In addition to significantly elevated SF at baseline 
(2195 μg/L—normal: 30-300 μg/L), patient no. 1 had sig-
nificantly elevated liver function enzymes (γ-glutamyl trans-
ferase [GGT], ALT, and AST) at baseline which was most 
likely associated with his high alcohol intake and he did not 
decrease his alcohol intake (his intake remained constant 
during the year that he participated in both the initial and 
the repeat studies). All 3 liver function enzymes (GGT, ALT, 
and AST) decreased during the 12 months on shogaol ther-
apy with ALT and AST falling (53% and 40%, respectively) 
to within normal range (Table 2). The decrease in SF and 
liver function enzymes seen in patient no. 1 was accompa-
nied by an increase in serum hepcidin in the repeat study 
(12.3-19.3 ng/mL—an increase in 57% from the start to the 
end of the repeat study; Table 2).
Table 2 shows the decrease in SF levels and liver function 
enzymes in patient no. 1 over both the initial study period (i) 
and the repeat study period (r) (SF decreased by 58% from ini-
tial baseline, GGT decreased by 19% from initial baseline, ALT 
decreased by 53% from initial baseline, AST decreased by 40% 
from initial baseline). Serum hepcidin levels were measured in 
the repeat study, and the table shows a 57% increase from 
repeat baseline.
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Table 1. Hematologic parameters, WHO type, and iron studies of the 6 early patients with MDS at the start of the initial study (SOS) and the end of 






























1 54/M RCMD SOS 151 3.6 1.76 29 95 28 56 2195 50
EOS 151 4.1 2.43 38 93 35.9 58 1071 62
2 64/M RCMD SOS 95 5.1 2.31 214 24 28 37 222 76
EOS 93 4.6 2.1 195 22 24 58 275 58
3 72/M RCMD SOS 108 2.9 1.48 114 76 22.4 50 709 45
EOS 101 1.7 0.67 94 61 29.4 48 387 61
4 72/F CMML-1 SOS 152 6.8 1.2 133 38 21.8 NA 94 36
EOS 137 9.5 2.7 148 52 10.5 NA 122 19
5 85/M RCMD SOS 94 6.5 3.27 193 165 10.7 48 336 22
EOS 125 4.5 2.05 79 122 16.8 56 117 30
6 75/F RARS SOS 91 5.4 2.61 467 32 29.5 44 198 67
EOS 88 5 2.18 464 34 35.7 44 227 81
Abbreviations: EOS, end of study; Hb, hemoglobin; neut., neutrophils; pltlts, platelets; RARS, refractory anemia with ringed sideroblast; RCC, red cell count; RCMD, 
refractory cytopenia with multilineage dysplasia; retic., reticulocytes; SOS, start of study; TiBC, total iron-binding capacity; WCC, white cell count; WHO, World Health 
Organization.
Figure 1. Serum ferritin (SF) levels of patient no. 1 during the initial (i) 
study, washout period and the repeat (r) study. The decrease in SF levels 
in patient no. 1 over 6-month period of initial study, stabilization during 
the washout period, and further decrease over 6-month repeat study 
period. Patient no. 1 showed a 58% decrease in SF levels from initial 
baseline.
Patient no. 3 had a 45% decrease in SF from baseline to 
6 months in the initial study (709-387 μg/L). During the 
3-month washout period, his SF levels increased (to 664 μg/L). 
Reintroduction of shogaol once again led to a decrease in SF (to 
390 μg/L; Figure 2). This decrease in SF remained at 45% from 
baseline in the repeat study. The decrease in SF was accompa-
nied by an increase in serum hepcidin in the repeat study (19 ng/
mL at start of repeat study to 42.2 ng/mL at end of repeat 
study). Liver function enzymes in this patient were within nor-
mal range during both the initial and repeat studies.
Discussion
The patients with lower risk MDS, whose disease is monitored 
on a “watch and wait” basis, represent the ideal conditions to 
test the role of nontoxic natural compounds. The rationale for 
using 6-shogaol in this small, investigative study is that both 
the ginger-derived 6-gingerol and 6-shogaol show anticarcino-
genic, hepatoprotective, and anti-inflammatory activities.8–10 
6-Shogaol has been found to have much stronger growth 
inhibitory effects than 6-gingerol on H1299 human lung can-
cer cells and HCT-116 human colon cancer cells.11
Although the 6-shogaol had no effect on cell counts, the 
results of our study show that 6-shogaol caused a decrease 
in SF levels in 3 of 6 patients with early MDS (50%) whose 
SF levels were elevated at the start of the study.
The decrease in SF level was reproduced in repeat studies 
in 2 patients. Neither had changed his dietary habits and 
urinary iron excretion remained normal during the study 
periods. The decrease in SF was accompanied by an increase 
in serum hepcidin level in both patients. A decrease in ele-
vated liver function enzymes was seen in patient 1 with a 
history of excess alcohol consumption, in keeping with prob-
able hepatoprotective activity of 6-shogaol.5,6
Our findings suggest upregulation of hepcidin and its pro-
hormones, with the resultant decrease in SF level attributable 
to decreased absorption of dietary iron. The improvement in 
liver function in patient 1 may reflect less cellular damage, as 
has been shown in animal studies by Zhuang and Alqasoumi.5,6
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In light of the encouraging results in this small, investigative 
study, we are planning a larger study to confirm the beneficial 
effect of 6-shogaol in patients with MDS with raised SF due to 
ineffective erythropoiesis.
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Figure 2. Serum ferritin (SF) levels of patient no. 3 during the initial study 
(i), washout period, and the repeat (r) study. The decrease in SF levels in 
patient no. 3 over 6-month period of initial study, an increase in SF during 
the washout period, and further decrease over 6-month repeat study 
period. Patient no. 3 showed a 45% decrease in SF levels from initial 
baseline.
